Manuel Valdebran

Dr. Manuel Valdebran

Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, CA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
EKEric H. Kowalski
Eric H. Kowalski
DKDiana Kneiber
Diana Kneiber
MVManuel Valdebran
Manuel Valdebran
UPUmangi Patel
Umangi Patel
KAkyle amber
kyle amber
Prurigo nodualris (PN) is a chronic condition with highly pruritic, hyperkeratotic papules or nodules arising in the setting of chronic pruritus. While PN may serve as a phenotypic presentation of several underlying conditions such as atopic dermatitis, chronic kidney disease-related pruritus, and neurological diseases, it represents a distinct clinical entity that may persist despite the removal of the underlying cause, if one is identified. Neuronal proliferation, eosinophils, mast cells, and small-fiber neuropathy play a role in the production of pruritus in PN, although the exact mechanism has not yet been established. Identifying an underlying cause, if present, is essential to prevent recurrence of PN. Due to often present comorbidities, treatment is typically multimodal with utilization of topical and systemic therapies. We performed a PubMed/MEDLINE search for PN and present a review of recent developments in the treatment of PN. Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.

25 January 2023 in JID Innovations
Verified
Journal Article
Open access
CLCourtney Linkous
Courtney Linkous
APAngel D. Pagan
Angel D. Pagan
Chelsea ShopeChelsea Shope
Chelsea Shope
LALaura Andrews
Laura Andrews
ASAlan Snyder
Alan Snyder
MVManuel Valdebran
Manuel Valdebran
Laser speckle contrast imaging or laser speckle imaging (LSI) is a noninvasive imaging technology that can detect areas of dynamic perfusion or vascular flow. Thus, LSI has shown increasing diagnostic utility in various pathologies and has been employed for intraoperative, postoperative, and long-term monitoring in many medical specialties. Recently, LSI has gained traction in clinical dermatology because it can be effective in the assessment of pathologies that are associated with increased perfusion and hypervascularity compared with that of normal tissue. To date, LSI has been found to be highly accurate in monitoring skin graft reperfusion, determining the severity of burns, evaluating neurosurgical revascularization, assessing persistent perfusion in capillary malformations after laser therapy, and differentiating malignant and benign skin lesions. LSI affords the advantage of noninvasively assessing lesions before more invasive methods of diagnosis, such as tissue biopsy, while remaining inexpensive and exhibiting no adverse events to date. However, potential obstacles to its clinical use include tissue movement artifact, primarily qualitative data, and unclear impact on clinical practice given the lack of superiority data compared with the current standard-of-care diagnostic methods. In this review, we discuss the clinical applications of LSI in dermatology for use in the diagnosis and monitoring of vascular, neoplastic, and inflammatory skin conditions.

1 June 2017 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
PDF file
AEAmira Elbendary
Amira Elbendary
RXRuzeng Xue
Ruzeng Xue
MVManuel Valdebran
Manuel Valdebran
KTKara Melissa T. Torres
Kara Melissa T. Torres
KPKruti Parikh
Kruti Parikh
DEDirk M. Elston
Dirk M. Elston
Background: Paget disease, Bowen disease, and malignant melanoma in situ are intraepidermal neoplasms, characterized by the presence of pagetoid scatter of atypical cells in the epidermis. This study reviewed the frequency of select histologic criteria to validate their usefulness in the histologic distinction between these entities.Methods: One hundred forty-four specimens with the diagnosis of Bowen disease, 144 specimens with Paget disease (mammary and extramammary), and 144 specimens with malignant melanoma in situ were examined microscopically to define frequencies of select histologic criteria present in each disease.Results: Comparison between mammary Paget and extramammary Paget disease showed no significant differences in the features studied. Crushing of basal keratinocytes, presence of atypical cells in the corneum, and presence of large cells with amphophilic cytoplasm were significantly noted in Paget disease. Transition between the atypical clear cells and surrounding keratinocytes was absent in all cases of melanoma in situ and in 87 (60.4%) cases of Paget disease, but it was significantly associated with Bowen disease (98.6%). Dyskeratotic cells were significantly associated with Bowen disease cases.Conclusion: Our study demonstrated a practical histologic approach to differentiate between intraepidermal pagetoid neoplasms. Careful histologic study of the proposed criteria may reduce reliance on immunohistochemical stains.

18 January 2022 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
IRIndia Robinson
India Robinson
GLGabriella Santa Lucia
Gabriella Santa Lucia
ALAndraia Li
Andraia Li
NONathaniel Oberholtzer
Nathaniel Oberholtzer
JPJohn Plante
John Plante
MVManuel Valdebran
Manuel Valdebran
New therapies such as immune checkpoint blockers (ICB) have offered extended survival to patients affected by advanced melanoma. However, ICBs have demonstrated debilitating side effects on the joints, liver, lungs, skin, and gut. Several biomarkers have been identified for their role in predicting which patients better tolerate ICBs. Still, these biomarkers are limited by immunologic and genetic heterogeneity and the complexity of translation into clinical practice. Recent observational studies have suggested eosinophil counts, and serum levels of eosinophil cationic protein are significantly associated with prolonged survival in advanced‐stage melanoma. It is likely that eosinophils thereby modulate treatment response through mechanisms yet to be explored. Here, we review the functionality of eosinophils, their oncogenic role in melanoma and discuss how these mechanisms may influence patient response to ICBs and their implications in clinical practice.

1 November 2016 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
PDF file
YLYeqiang Liu
Yeqiang Liu
MVManuel Valdebran
Manuel Valdebran
JCJia Chen
Jia Chen
AEAmira Elbendary
Amira Elbendary
FWFei Wu
Fei Wu
MXMinyuan Xu
Minyuan Xu

1 November 2016 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
MVManuel Valdebran
Manuel Valdebran
AEAmira Elbendary
Amira Elbendary
SASri Krishna Chaitanya Arudra
Sri Krishna Chaitanya Arudra
KTKara Melissa Torres
Kara Melissa Torres
IEInas Elattar
Inas Elattar
DEDirk M. Elston
Dirk M. Elston